Banca de QUALIFICAÇÃO: TAINAH AZEVEDO VENCESLAU

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : TAINAH AZEVEDO VENCESLAU
DATE: 23/11/2026
TIME: 14:00
LOCAL: Google Meet
TITLE:

Safety profile and factors associated with adverse reactions to anti-TNF medications in patients with rheumatoid arthritis and ankylosing spondylitis: a cross-sectional study in a real-world setting


KEY WORDS:

Rheumatic Diseases; Antirheumatic Agents; Tumor Necrosis Factor Antagonists; Biological Products; Pharmacovigilance.


PAGES: 40
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUBÁREA: Farmácia clínica, assistência e atenção farmacêuticas
SUMMARY:

Introduction: Rheumatic diseases significantly impair patients’ quality of life. Among the available pharmacological treatment options, the efficacy of biological drugs in the anti-tumor necrosis factor (anti-TNF) class has increased the confidence of healthcare professionals and patients, making disease remission an increasingly realistic goal. However, evidence suggests an increased risk of serious infections in these patients, and estimates indicate that approximately 40% of individuals treated with these drugs either do not respond to therapy or experience a loss of response over time. Objective: In this context, this study aimed to characterize the utilization and safety profiles of anti-TNF drugs, as well as the factors associated with treatment failure in patients with rheumatic diseases. Methods: Na observational, cross-sectional study was conducted involving 600 patients receiving biological drugs from the anti-TNF class dispensed by the Central Therapeutic Agents Unit (Unidade Central de Agentes Terapêuticos – UNICAT) in Natal, Brazil. Results: Among the patients evaluated, 274 (45.7%) reported adverse drug reactions (ADRs), primarily cutaneous manifestations (32.5%) and flu-like symptoms (11.5%). Certolizumab pegol had the highest frequency of ADRs (59.5%), followed by golimumab (45.4%), adalimumab (40.5%), and etanercept (32.5%). Regarding the time of onset, ADRs were concentrated predominantly on the first day after administration, with 20 cases per 100 patients, decreasing to 1 case per 100 patients on the second day. Multivariate analysis identified female sex (OR: 2.38; 95% CI:1.62–3.51), younger age (OR: 0.97; 95% CI: 0.96–0.98), recent clinical exacerbation (OR: 1.52; 95% CI: 1.08–2.13), and recent antimicrobial use (OR: 1.81; 95% CI: 1.18–2.77) as independent risk factors. Conclusion: These findings may contribute to strengthening healthcare policies aimed at improving patient care and reducing the occurrence of drug related problems.


COMMITTEE MEMBERS:
Externa à Instituição - GIRLANDIA ALEXANDRE BRASIL AMORIM
Externo ao Programa - 1674779 - NEY MOURA LEMOS PEREIRA - nullPresidente - 1052612 - RODRIGO DOS SANTOS DINIZ
Notícia cadastrada em: 12/11/2026 09:52
SIGAA | Superintendência de Tecnologia da Informação - (84) 3342 2210 | Copyright © 2006-2026 - UFRN - sigaa10-producao.info.ufrn.br.sigaa10-producao